Glenmark acquires marketing rights to three generic products for pain from Aspen

By Lisa Kerner

Erie, Pa., May 8 - Glenmark Pharmaceuticals Ltd.'s wholly owned subsidiary, Glenmark Pharmaceuticals Inc. USA, signed a supply and marketing agreement with Aspen USA, Inc. for the joint manufacturing and marketing of three generic controlled-substance pharmaceutical products for the U.S. market.

The solid-dose formulation products for pain management have a cumulative market size of about $44 million, with limited competition, according to a company news release.

Under the agreement, Aspen will supply the products to Glenmark Pharmaceuticals Inc. to be marketed under the Glenmark label. The products are expected to launch over a three-month period beginning in May.

Glenmark will pay Aspen an initial milestone for the exclusive marketing rights to the products. Both Glenmark and Aspen will share in the profits on net sales in the U.S. market.

Last week, Glenmark announced an in-licensing agreement with Lehigh Valley Technologies, Inc. (LVT) for two liquid controlled-drug substances.

The company said it has also concluded deals with InvaGen Pharmaceuticals Inc. and Shasun Chemicals and Drugs Ltd. for the development and marketing of a total of 20 generic products for the U.S. market.

"Our deal with Aspen along with the recent deal with LVT will provide our U.S. operations a head start in establishing a U.S. franchise in the less-competitive space of controlled drug substances," managing director and chief executive officer Glenn Saldanha said in the release.

"It will also significantly add to the six products that we currently have in market and will go a long way in strengthening our generics presence in the U.S."

The company said it is anticipating approvals for an additional two to four abbreviated New Drug Applications and plans to have at 18 to 24 generic products in the U.S. market by the end of 2007.

Glenmark is a Mumbai, India-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.